A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function.
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Latrepirdine (Primary)
- Indications Alzheimer's disease; Huntington's disease
- Focus Pharmacokinetics
- Sponsors Pfizer
- 17 Sep 2009 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 17 Sep 2009 Actual initiation date changed from Jan 2009 to Feb 2009 as reported by ClinicalTrials.gov.
- 17 Sep 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.